Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MINERVA SURGICAL INCUTRS · Entity 115564 | Director · 10% owner | February 09, 2023 | February 09, 2023 |
| NeuroPace IncNPCE · Entity 5459 | Director | June 19, 2026 | June 22, 2026 |
| STRATA Skin Sciences, Inc.SSKN · Entity 72980 | Director · 10% owner | July 15, 2024 | July 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MINERVA SURGICAL INC
Report date February 09, 2023 · Filed February 09, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 122,189,638 |
Reported balance
Holding disclosure · report date 2023-02-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 122,189,638 F1: Shares are held by Accelmed Partners II L.P. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP L.P., which is the general partner of Accelmed Partners II L.P. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II L.P. Dr. Geiger, a member of Minerva Surgical, Inc.'s board of directors, is a General Partner at Accelmed LLC. The address of each of Accelmed LLC, Accelmed Partners II GP L.P., Accelmed Partners II L.P. and Dr. Geiger is Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held by Accelmed Partners II L.P. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP L.P., which is the general partner of Accelmed Partners II L.P. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II L.P. Dr. Geiger, a member of Minerva Surgical, Inc.'s board of directors, is a General Partner at Accelmed LLC. The address of each of Accelmed LLC, Accelmed Partners II GP L.P., Accelmed Partners II L.P. and Dr. Geiger is Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
NeuroPace Inc
Report date June 19, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,537 |
Reported balance
After 2026-06-19 transaction · row 1
1 source rowRow 1 · 2026-06-19 · Grant · Acquired 789 · Balance 18,537 F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 4,432,948 |
Reported balance
Holding disclosure · report date 2026-06-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,432,948 F2: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
F2: Shares are held by Accelmed Partners II LP. Accelmed Partners II, LLC ("Accelmed LLC") is the general partner of Accelmed Partners II GP, L.P., which is the general partner of Accelmed Partners II LP. Uri Geiger is the managing partner of Accelmed LLC and has sole voting and dispositive power with respect to the shares held by Accelmed Partners II LP. Dr. Geiger, a member of our board of directors, is a General Partner at Accelmed LLC.
STRATA Skin Sciences, Inc.
Report date July 15, 2024 · Filed July 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,441,835 |
Reported balance
After 2024-07-15 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-07-15 · Purchase · Acquired 230,573 · Balance 1,441,835 F1: Shares are held directly by Accelmed Partners, L.P. The reporting person is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Partners (GP), L.P., which is the general partner of Accelmed Partners, L.P. and as a result he may be deemed to beneficially own the shares of common stock held by Accelmed Partners, L.P. The reporting person is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the shares of common stock owned by Accelmed Partners, L.P. pursuant to a management agreement, and as a result the reporting person may be deemed to beneficially own the shares of the common stock held by Accelmed Partners, L.P. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares are held directly by Accelmed Partners, L.P. The reporting person is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Partners (GP), L.P., which is the general partner of Accelmed Partners, L.P. and as a result he may be deemed to beneficially own the shares of common stock held by Accelmed Partners, L.P. The reporting person is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the shares of common stock owned by Accelmed Partners, L.P. pursuant to a management agreement, and as a result the reporting person may be deemed to beneficially own the shares of the common stock held by Accelmed Partners, L.P. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COGENTIX MEDICAL INC /DE/
Report date April 20, 2018 · Filed April 23, 2018
Section 16 reporting ended · disclosed 2018-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote 2 | 0 |
Reported balance
After 2018-04-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-04-20 · Other · Disposed 16,129,033 · Balance 0 F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). F2: Consists of 16,129,033 shares of the common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Growth Partners (GP), L.P., which is the general partner of Accelmed Growth Partners, L.P., and as a result Uri Geiger may be deemed to beneficially own the shares of common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the 16,129,033 shares of common stock owned by Accelmed Growth Partners, L.P. pursuant to a management agreement, and as a result Uri Geiger may be deemed to beneficially own the shares of the common stock held by Accelmed Growth Partners, L.P. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement").
F2: Consists of 16,129,033 shares of the common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Growth Partners (GP), L.P., which is the general partner of Accelmed Growth Partners, L.P., and as a result Uri Geiger may be deemed to beneficially own the shares of common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the 16,129,033 shares of common stock owned by Accelmed Growth Partners, L.P. pursuant to a management agreement, and as a result Uri Geiger may be deemed to beneficially own the shares of the common stock held by Accelmed Growth Partners, L.P.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 22, 2026 20:34 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 789 | $15.63 | $12,332.07 |
DisclosureSEC source: 0001467361-26-000005 · wk-form4_1782160441.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,537 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 5,368 | $0.00 Strike: $15.74 | $0.00 |
DisclosureSEC source: 0001467361-26-000003 · wk-form4_1780693831.xml · derivative · entry 3 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,368 Underlying: Common Stock · 5,368 shares Expires 2036-06-04 F3 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| June 05, 2026 Filed Jun 5, 2026 21:10 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001467361-26-000003 · wk-form4_1780693831.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,748 F1 · shares: The shares shall vest in twelve (12) equal consecutive monthly installments until all of the shares are fully vested, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 20:47 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 913 | $13.00 | $11,869.00 |
DisclosureSEC source: 0001628280-26-020837 · wk-form4_1774385234.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,858 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 21:15 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 715 | $16.59 | $11,861.85 |
DisclosureSEC source: 0001467361-25-000005 · form4-12232025_041220.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,945 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 19, 2025 Filed Sep 22, 2025 23:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,194 | $9.94 | $11,868.36 |
DisclosureSEC source: 0001467361-25-000003 · form4-09222025_070908.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,230 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,140 | $10.41 | $11,867.40 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 9 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,036 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 21:26 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (right to buy) · Derivative | 8,745 | $0.00 Strike: $13.15 | $0.00 |
DisclosureSEC source: 0001415889-25-016326 · form4-06092025_050606.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,745 Underlying: Common Stock · 8,745 shares Expires 2035-06-05 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
| March 21, 2025 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 987 | $12.02 | $11,863.74 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 8 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,896 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 21, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,029 | $11.53 | $11,864.37 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 7 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,909 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 30, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,703 | $6.97 | $11,869.91 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 6 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,880 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 17:08 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | PurchaseCommon Stock | 230,573 | $3.14 | $723,999.22 |
DisclosureSEC source: 0001213900-24-062198 · ownership.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,441,835 F1 · ownership.nature: Shares are held directly by Accelmed Partners, L.P. The reporting person is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Partners (GP), L.P., which is the general partner of Accelmed Partners, L.P. and as a result he may be deemed to beneficially own the shares of common stock held by Accelmed Partners, L.P. The reporting person is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the shares of common stock owned by Accelmed Partners, L.P. pursuant to a management agreement, and as a result the reporting person may be deemed to beneficially own the shares of the common stock held by Accelmed Partners, L.P. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein. Read SEC document |
| June 28, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,570 | $7.56 | $11,869.20 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 5 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,177 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 07, 2024 Filed Jun 11, 2024 20:15 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 17,774 | $0.00 Strike: $6.47 | $0.00 |
DisclosureSEC source: 0001415889-24-016357 · form4-06112024_080644.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,774 Underlying: Common Stock · 17,774 shares Expires 2034-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| March 29, 2024 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 899 | $13.20 | $11,866.80 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 4 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,607 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| December 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,151 | $10.31 | $11,866.81 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 3 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,708 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| September 29, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 1,220 | $9.73 | $11,870.60 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 2 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,557 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 30, 2023 Filed Jun 24, 2025 20:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantCommon Stock | 2,337 | $4.49 | $10,493.13 |
DisclosureSEC source: 0001415889-25-018091 · form4-06242025_040607.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,337 F1 · shares: These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees. Read SEC document |
| June 07, 2023 Filed Jun 14, 2023 20:58 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Rt to Buy) · Derivative | 27,380 | $0.00 Strike: $4.20 | $0.00 |
DisclosureSEC source: 0001209191-23-037075 · doc4.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,380 Underlying: Common Stock · 27,380 shares Expires 2033-06-06 F1 · derivative.exercise_date: The shares subject to the option shall vest in twelve (12) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:30 UTC | NeuroPace Inc NPCE · Entity 5459 | GrantStock Option (Right to Buy) · Derivative | 120,521 | $0.00 Strike: $1.54 | $0.00 |
DisclosureSEC source: 0001209191-23-002565 · doc4.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,521 Underlying: Common Stock · 120,521 shares Expires 2033-01-04 F1 · derivative.exercise_date: The shares subject to the option shall vest in thirty six (36) equal consecutive monthly installments until all of the option shares are fully vested and exercisable. Read SEC document |
| June 15, 2018 Filed Sep 10, 2018 11:03 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | OtherSSKN Common Stock | 75,590 | $1.09 | $82,393.10 |
DisclosureSEC source: 0001567619-18-002345 · doc1.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · see footnote Disclosed balance after: 12,122,627 F1 · kind: 6/15/18 the reporting person was entitled to receive 75,590 shares of the common stock pursuant to a "retained risk" provision in the Securities Purchase Agreement between the Company and Accelmed Growth Partners, L.P. dated 5/29/18 ("Purchase Agreement"). Purchase Agreement provided that the purchaser would receive additional shares of common stock in the event of certain contingent expense events, one of which was determined to have occurred on 6/15/18, resulted in the purchaser acquired additional shares. The number of shares issuable pursuant to that provision, determined on 6/15/18 pursuant to a formula set forth in the Purchase Agreement provided that, for purposes of determining the number of shares issuable, the common stock would be valued at $1.09 per share, which was the purchase price of the common stock in the Purchase Agreement. F1 · shares: 6/15/18 the reporting person was entitled to receive 75,590 shares of the common stock pursuant to a "retained risk" provision in the Securities Purchase Agreement between the Company and Accelmed Growth Partners, L.P. dated 5/29/18 ("Purchase Agreement"). Purchase Agreement provided that the purchaser would receive additional shares of common stock in the event of certain contingent expense events, one of which was determined to have occurred on 6/15/18, resulted in the purchaser acquired additional shares. The number of shares issuable pursuant to that provision, determined on 6/15/18 pursuant to a formula set forth in the Purchase Agreement provided that, for purposes of determining the number of shares issuable, the common stock would be valued at $1.09 per share, which was the purchase price of the common stock in the Purchase Agreement. F1 · price: 6/15/18 the reporting person was entitled to receive 75,590 shares of the common stock pursuant to a "retained risk" provision in the Securities Purchase Agreement between the Company and Accelmed Growth Partners, L.P. dated 5/29/18 ("Purchase Agreement"). Purchase Agreement provided that the purchaser would receive additional shares of common stock in the event of certain contingent expense events, one of which was determined to have occurred on 6/15/18, resulted in the purchaser acquired additional shares. The number of shares issuable pursuant to that provision, determined on 6/15/18 pursuant to a formula set forth in the Purchase Agreement provided that, for purposes of determining the number of shares issuable, the common stock would be valued at $1.09 per share, which was the purchase price of the common stock in the Purchase Agreement. F2 · ownership.nature: Consists of 12,112,627 shares of the common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Growth Partners (GP), L.P., which is the general partner of Accelmed Growth Partners, L.P. and as a result Uri Geiger may be deemed to beneficially own the shares of common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the 12,112,627 shares of common stock owned by Accelmed Growth Partners, L.P. pursuant to a management agreement, and as a result Uri Geiger may be deemed to beneficially own the shares of the common stock held by Accelmed Growth Partners, L.P. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 18:23 UTC | STRATA Skin Sciences, Inc. SSKN · Entity 72980 | GrantSTRATA Restricted Stock Units · Derivative | 19,324 | $0.00 Strike: $2.07 | $0.00 |
DisclosureSEC source: 0001140361-18-028131 · doc1.xml · derivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,324 Underlying: Common Stock · 19,324 shares Expires 2028-06-08 F1 · derivative.exercise_date: Restricted Stock Options will vest 100%, in equal quarterly installments, over a 12 month period. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 17:05 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | OtherCommon Stock | 16,129,033 | $3.85 | $62,096,777.05 |
DisclosureSEC source: 0001437749-18-007486 · rdgdoc.xml · nonDerivative · entry 1 Geiger Uri · CIK 0001467361 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote 2 Disclosed balance after: 0 F1 · shares: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). F2 · ownership.direct: Consists of 16,129,033 shares of the common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling member and managing partner of Accelmed Growth Partners (AGP) Limited, which is the general partner of Accelmed Growth Partners (GP), L.P., which is the general partner of Accelmed Growth Partners, L.P., and as a result Uri Geiger may be deemed to beneficially own the shares of common stock held by Accelmed Growth Partners, L.P. Uri Geiger is the controlling shareholder and managing partner of Accelmed Growth Partners Management Ltd., which has certain voting and dispositive power over the 16,129,033 shares of common stock owned by Accelmed Growth Partners, L.P. pursuant to a management agreement, and as a result Uri Geiger may be deemed to beneficially own the shares of the common stock held by Accelmed Growth Partners, L.P. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.